family with sequence similarity 133, member A pseudogeneGenealiases: []
Q-omics provides the consensus-scored FAM133CP profile across patient tissues and cancer cell-line models. FAM133CP expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, FAM133CP is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, FAM133CP RNA expression shows 13,285 significant gene co-expression associations, with the highest sampling consensus in KICH. Together, these results highlight KICH, and KIRC as cancer lineages where FAM133CP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM133CP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM133CP survival associations across molecular data types. FAM133CP RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM133CP RNA expression–survival associations across cancer types. High FAM133CP expression shows unfavorable associations in KICH, KIRC, UCEC, DLBC and LUAD, but favorable associations in LUSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KICH as the clearest survival context for FAM133CP RNA expression.
This table summarizes FAM133CP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM133CP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM133CP shows lower tumor expression in KIRC, KICH and THCA and higher tumor expression in COAD, HNSC and CHOL. The KIRC box plot shows higher FAM133CP RNA expression in normal versus tumor tissue (log2 FC = −0.261, t-test p < 0.001).
This table shows molecular features associated with FAM133CP in patient tissues and cancer cell lines. In patient samples, FAM133CP shows the broadest associations at the RNA and protein expression levels, with KICH recurring as the lineage with the largest associated feature set.
